264 related articles for article (PubMed ID: 25247583)
1. Review of tenofovir use in HIV-infected children.
Aurpibul L; Puthanakit T
Pediatr Infect Dis J; 2015 Apr; 34(4):383-91. PubMed ID: 25247583
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.
Della Negra M; De Carvalho AP; De Aquino MZ; Pinto JA; Da Silva MT; Andreatta KN; Graham B; Liu YP; Quirk EK
Pediatr Infect Dis J; 2015 Apr; 34(4):398-405. PubMed ID: 25599284
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients.
Bouazza N; Urien S; Hirt D; Frange P; Rey E; Benaboud S; Foissac F; Blanche S; Tréluyer JM
J Acquir Immune Defic Syndr; 2011 Nov; 58(3):283-8. PubMed ID: 21857359
[TBL] [Abstract][Full Text] [Related]
6. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
Saez-Llorens X; Castaño E; Rathore M; Church J; Deville J; Gaur A; Estripeaut D; White K; Arterburn S; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
Pediatr Infect Dis J; 2015 Apr; 34(4):376-82. PubMed ID: 25760565
[TBL] [Abstract][Full Text] [Related]
7. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
Pontrelli G; Cotugno N; Amodio D; Zangari P; Tchidjou HK; Baldassari S; Palma P; Bernardi S
BMC Infect Dis; 2012 Jan; 12():18. PubMed ID: 22269183
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland.
Riordan A; Judd A; Boyd K; Cliff D; Doerholt K; Lyall H; Menson E; Butler K; Gibb D;
Pediatr Infect Dis J; 2009 Mar; 28(3):204-9. PubMed ID: 19209091
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
Pujari S; Dravid A; Gupte N; Joshi K; Bele V
Medscape J Med; 2008; 10(8):196. PubMed ID: 18924648
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.
Mirochnick M; Taha T; Kreitchmann R; Nielsen-Saines K; Kumwenda N; Joao E; Pinto J; Santos B; Parsons T; Kearney B; Emel L; Herron C; Richardson P; Hudelson SE; Eshleman SH; George K; Fowler MG; Sato P; Mofenson L;
J Acquir Immune Defic Syndr; 2014 Jan; 65(1):33-41. PubMed ID: 23979002
[TBL] [Abstract][Full Text] [Related]
12. Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
Young B; Weidle PJ; Baker RK; Armon C; Wood KC; Moorman AC; Holmberg SD;
AIDS Patient Care STDS; 2006 Apr; 20(4):238-44. PubMed ID: 16623622
[TBL] [Abstract][Full Text] [Related]
13. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.
Colbers AP; Hawkins DA; Gingelmaier A; Kabeya K; Rockstroh JK; Wyen C; Weizsäcker K; Sadiq ST; Ivanovic J; Giaquinto C; Taylor GP; Moltó J; Burger DM;
AIDS; 2013 Mar; 27(5):739-48. PubMed ID: 23169329
[TBL] [Abstract][Full Text] [Related]
14. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Apr; 54(4):378-85. PubMed ID: 24142299
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.
Winston J; Chonchol M; Gallant J; Durr J; Canada RB; Liu H; Martin P; Patel K; Hindman J; Piontkowsky D
HIV Clin Trials; 2014; 15(6):231-45. PubMed ID: 25433663
[TBL] [Abstract][Full Text] [Related]
16. A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: a report from 5 years of clinical experience.
Rosso R; Parodi A; Torrisi C; De Terlizzi F; Viscoli C; Vignolo M
AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1265-6. PubMed ID: 20874420
[No Abstract] [Full Text] [Related]
17. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents.
Della Negra M; de Carvalho AP; de Aquino MZ; da Silva MT; Pinto J; White K; Arterburn S; Liu YP; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
Pediatr Infect Dis J; 2012 May; 31(5):469-73. PubMed ID: 22301477
[TBL] [Abstract][Full Text] [Related]
18. Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.
Uglietti A; Zanaboni D; Gnarini M; Maserati R
Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1305-14. PubMed ID: 22943210
[TBL] [Abstract][Full Text] [Related]
19. Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.
Havens PL; Hazra R
Pediatr Infect Dis J; 2015 Apr; 34(4):406-8. PubMed ID: 25599283
[No Abstract] [Full Text] [Related]
20. Long-term treatment with tenofovir: prevalence of kidney tubular dysfunction and its association with tenofovir plasma concentration.
Ezinga M; Wetzels JF; Bosch ME; van der Ven AJ; Burger DM
Antivir Ther; 2014; 19(8):765-71. PubMed ID: 24584104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
